• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

强调铂类化疗药物的免疫调节作用的重要性。

STATing the importance of immune modulation by platinum chemotherapeutics.

机构信息

Department of Tumor Immunology; Radboud University Medical Centre and Nijmegen Centre for Molecular Life Sciences; Nijmegen, The Netherlands.

出版信息

Oncoimmunology. 2012 Mar 1;1(2):234-236. doi: 10.4161/onci.1.2.18126.

DOI:10.4161/onci.1.2.18126
PMID:22720254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3376994/
Abstract

Platinum-based anticancer drugs enhance the immunostimulatory potential of DCs and decrease the immunosuppressive capacity of tumor cells. This immunomodulatory ability is based on the inhibition of STAT6-mediated expression of co-inhibitory molecule PD-L2 and opens up the possibility of using these drugs in combination with other immunostimulatory compounds.

摘要

基于铂类的抗癌药物增强了 DC 的免疫刺激潜能，并降低了肿瘤细胞的免疫抑制能力。这种免疫调节能力基于抑制 STAT6 介导的共抑制分子 PD-L2 的表达，为这些药物与其他免疫刺激化合物联合使用开辟了可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/445a/3376994/5075d1aa5184/onci-1-234-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/445a/3376994/5075d1aa5184/onci-1-234-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/445a/3376994/5075d1aa5184/onci-1-234-g1.jpg

相似文献

1
STATing the importance of immune modulation by platinum chemotherapeutics.强调铂类化疗药物的免疫调节作用的重要性。
Oncoimmunology. 2012 Mar 1;1(2):234-236. doi: 10.4161/onci.1.2.18126.
2
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.铂类药物会破坏 STAT6 介导的对人类和小鼠体内肿瘤免疫反应的抑制作用。
J Clin Invest. 2011 Aug;121(8):3100-8. doi: 10.1172/JCI43656. Epub 2011 Jul 18.
3
STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics.STAT 家族蛋白在 moDC 发育过程中的表达和磷酸化状态受铂类化疗药物的影响。
J Immunol Res. 2019 Jun 11;2019:7458238. doi: 10.1155/2019/7458238. eCollection 2019.
4
Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.促炎型壳聚糖/聚（γ-谷氨酸）纳米粒调节人抗原呈递细胞表型并逆转其促侵袭能力。
Acta Biomater. 2017 Nov;63:96-109. doi: 10.1016/j.actbio.2017.09.016. Epub 2017 Sep 14.
5
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.铂类化疗联合 PD-1/PD-L1 抑制剂：临床前和临床研究及作用机制。
Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. doi: 10.1080/17425247.2021.1825376. Epub 2020 Oct 5.
6
Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.替代激活的巨噬细胞通过 Stat6 依赖性表达 PD-L2 抑制 T 细胞增殖。
Blood. 2010 Oct 28;116(17):3311-20. doi: 10.1182/blood-2010-02-271981. Epub 2010 Jul 12.
7
Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors.钙调神经磷酸酶抑制剂增强丙型肝炎病毒感染肝细胞上的程序性死亡配体2
Transplantation. 2015 Jul;99(7):1447-54. doi: 10.1097/TP.0000000000000572.
8
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.人CD1c(+)树突状细胞是由免疫原性细胞死亡诱导的免疫反应的关键细胞介质。
Oncoimmunology. 2016 Aug 3;5(8):e1192739. doi: 10.1080/2162402X.2016.1192739. eCollection 2016 Aug.
9
Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.具有抑制和靶向作用机制的铂类化疗药物的最新进展。
J Inorg Biochem. 2020 Jun;207:111070. doi: 10.1016/j.jinorgbio.2020.111070. Epub 2020 Mar 23.
10
Dexamethasone counteracts the immunostimulatory effects of triiodothyronine (T3) on dendritic cells.地塞米松可拮抗三碘甲状腺原氨酸（T3）对树突状细胞的免疫刺激作用。
Steroids. 2012 Jan;77(1-2):67-76. doi: 10.1016/j.steroids.2011.10.006. Epub 2011 Oct 25.

引用本文的文献

1
The Role of Platinum-Based Chemotherapy in the Pathogenesis of Tendinosis in Cancer Patients.铂类化疗在癌症患者肌腱病发病机制中的作用。
Cureus. 2025 Jul 12;17(7):e87791. doi: 10.7759/cureus.87791. eCollection 2025 Jul.
2
Platinum-based drugs and hydrogel: a promising anti-tumor combination.铂类药物与水凝胶：一种有前途的抗肿瘤联合疗法。
Drug Deliv. 2023 Dec;30(1):2287966. doi: 10.1080/10717544.2023.2287966. Epub 2023 Dec 11.
3
The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.脑胶质瘤中当前铂类抗癌药物耐药的机制。

本文引用的文献

1
Cancer immunotherapy--revisited.癌症免疫疗法——再探。
Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500.
2
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.铂类药物会破坏 STAT6 介导的对人类和小鼠体内肿瘤免疫反应的抑制作用。
J Clin Invest. 2011 Aug;121(8):3100-8. doi: 10.1172/JCI43656. Epub 2011 Jul 18.
3
STAT6 expression in glioblastoma promotes invasive growth.STAT6 在胶质母细胞瘤中的表达促进了浸润性生长。
Curr Pharm Des. 2022;28(23):1863-1869. doi: 10.2174/1381612828666220607105746.
4
Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.重新审视基于铂类的抗癌药物以克服神经胶质瘤。
Int J Mol Sci. 2021 May 12;22(10):5111. doi: 10.3390/ijms22105111.
5
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.一项关于顺铂-帕博利珠单抗联合化疗免疫疗法及放疗用于不可切除外阴鳞状细胞癌的2期研究。
J Transl Med. 2020 Sep 14;18(1):350. doi: 10.1186/s12967-020-02523-5.
6
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.奥沙利铂可破坏胶质瘤细胞和相关巨噬细胞的病理特征，而不依赖于细胞凋亡的诱导。
J Neurooncol. 2018 Dec;140(3):497-507. doi: 10.1007/s11060-018-2979-1. Epub 2018 Aug 21.
7
Under-Reported Aspects of Platinum Drug Pharmacology.铂类药物药理学的未充分报道方面。
Molecules. 2017 Feb 28;22(3):382. doi: 10.3390/molecules22030382.
8
Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.超越化疗引起的周围神经病的症状缓解：针对根源。
Cancer. 2018 Jun 1;124(11):2289-2298. doi: 10.1002/cncr.31248. Epub 2018 Feb 20.
9
Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.铂类药物对信号转导和转录激活因子（STAT）信号的直接抑制作用有助于其抗癌活性。
Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.
10
Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.癌细胞的异质性：不同原发性和继发性结直肠癌细胞系在体外对药物反应的差异
In Vitro Cell Dev Biol Anim. 2017 May;53(5):435-447. doi: 10.1007/s11626-016-0126-x. Epub 2017 Jan 24.
BMC Cancer. 2011 May 20;11:184. doi: 10.1186/1471-2407-11-184.
4
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.在结肠癌患者中，树突状细胞疫苗接种在辅助奥沙利铂/卡培他滨化疗期间的免疫原性的初步研究。
Br J Cancer. 2010 Oct 26;103(9):1415-21. doi: 10.1038/sj.bjc.6605935. Epub 2010 Oct 5.
5
EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.EZH2 和 STAT6 的表达谱与结直肠癌的分期和预后相关。
World J Gastroenterol. 2010 May 21;16(19):2421-7. doi: 10.3748/wjg.v16.i19.2421.
6
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.化疗增强了癌症免疫治疗中 CTL 介导的杀伤肿瘤细胞的敏感性。
J Clin Invest. 2010 Apr;120(4):1111-24. doi: 10.1172/JCI40269. Epub 2010 Mar 15.
7
PD-1 and its ligands in tolerance and immunity.PD-1及其配体在免疫耐受与免疫中的作用
Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
8
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.免疫系统通过Toll样受体4对癌症化疗和放疗的作用
Nat Med. 2007 Sep;13(9):1050-9. doi: 10.1038/nm1622. Epub 2007 Aug 19.
9
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.乳腺癌指导树突状细胞启动分泌白细胞介素13的CD4+ T细胞，从而促进肿瘤发展。
J Exp Med. 2007 May 14;204(5):1037-47. doi: 10.1084/jem.20061120. Epub 2007 Apr 16.
10
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.程序性死亡蛋白1配体-1和程序性死亡蛋白1配体-2在人食管癌中的表达的临床意义
Clin Cancer Res. 2005 Apr 15;11(8):2947-53. doi: 10.1158/1078-0432.CCR-04-1469.